Oncotelic Therapeutics Inc. (OTLC) Champions Targeted RNA Therapy for Underserved Cancers
On the global stage, the Cancer Atlas estimates a dramatic rise in cancer cases, adding urgency to the need for therapeutic innovation Oncotelic’s mission focuses on developing first-in-class RNA therapeutics and small-molecule drugs to serve high-unmet-need cancers and rare pediatric diseases This year, the company achieved a major milestone by successfully completing a phase 1 clinical trial evaluating OT-101 combining Interleukin-2 In a landscape where cancer and underserved diseases continue to devastate millions, the demand for groundbreaking RNA-based, immunotherapeutic, and targeted treatments has never been more urgent. Oncotelic Therapeutics (OTCQB: OTLC) is answering this call with pioneering RNA candidates and strategic programs aimed at…